Biotech Values

[mcbio]

MEIP

"The enthusiasm surrounding this open-label study continues to mount, as evidenced by the rapid rate of enrollment over the past six months," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma. "Not only are we seeing a higher initial response rate than expected from azacitidine alone, often within the first two cycles, but these patients are continuing to improve with subsequent treatment. We look forward to reporting additional interim data, including duration of response, at ASH on Saturday."

Why didn't MEIP run a controlled trial comparing pracinostat+azacitidine to placebo+azacitidine so we could truly gauge how much pracinostat itself is contributing to this data?